Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Maira, Sauveur-Michel; Stauffer, Frédéric; Brueggen, Josef; Furet, Pascal; Schnell, Christian; Fritsch, Christine; M. Brachmann, Saskia; Chêne, Patrick; De Pover, Alain; Schoemaker, Kevin; Fabbro, Doriano; Gabriel, Daniela; Simonen, Marjo; O. Murphy, Leon; M. Finan, Peter; R. Sellers, William; García-Echeverría, Carlos

doi:10.1158/1535-7163.mct-08-0017

Public

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Published in Molecular Cancer Therapeutics • Jul 1, 2008

Authors:

Sauveur-Michel Maira

Frédéric Stauffer

Josef Brueggen

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention. NVP-BEZ235 is an imidazo[4,5-c]quinoline derivative that inhibits PI3K a...

Subject

PI3K/AKT/mTOR pathway

In vivo

Pharmacology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!